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The goal of immunotherapy is to enhance the ability of the immune system to kill 
cancer cells. Immunotherapy is more effective and, in general, the prognosis is better, 
when more immune cells infiltrate the tumor. We explore the question of whether the 
spatial distribution rather than just the density of immune cells in the tumor is important 
in forecasting whether cancer recurs. After reviewing previous work on this issue, we 
introduce a novel application of maximum entropy to quantify the spatial distribution of 
discrete point-like objects. We apply our approach to B and T cells in images of tumor 
tissue taken from triple negative breast cancer (TBNC) patients. We find that there is a 
distinct difference in the spatial distribution of immune cells between good clinical 
outcome (no recurrence of cancer within at least 5 years of diagnosis) and poor clinical 
outcome (recurrence within 3 years of diagnosis). Our results highlight the importance 
of spatial distribution of immune cells within tumors with regard to clinical outcome, and 
raise new questions on their role in cancer recurrence. 
 
Introduction 
Why physicists? 
Why should physicists pay attention to cancer as a research topic? Traditionally, cancer 
research has been the purview of biologists and medical researchers. Yet, despite the 
billions of dollars that have been spent on the war on cancer, far too many people are 
still battling this disease. Consider the following statistics. Worldwide, in 2012, 
approximately 14 million new cases of cancer were diagnosed and 8 million people died 
of cancer (15% of deaths) [1]. In the United States alone about 600,000 people die of 
cancer each year [2]. This accounts for 1 in 4 deaths. It is estimated that during their 
lifetime, one in two men and one in three women will be diagnosed with cancer [3]. 
These statistics highlight the need for new ways of thinking. As a result, interdisciplinary 
collaborations involving cancer researchers, physicists, mathematicians, engineers and 
computer scientists have been working to hasten progress with new techniques and 
different approaches. 
 
To compare and contrast the types of problems that physicists and biologists study, 
consider a typical biological approach that emphasizes signaling pathways. (A signaling 
pathway is a sequence of switches in a cell in which protein A activates or deactivates 
protein B that in turn switches protein C on or off, etc. Proteins are molecular machines 
that perform various jobs in the cell.) Cancer research typically focuses on signaling 
pathways that have been over-activated or deactivated due to gene mutations. These 
aberrant signaling pathways enable a tumor to grow and spread. The goal is to develop 
therapeutics targeting these pathways on which the growing tumor depends. Yet, all too 
often these chemotherapy drugs, combined with surgery and radiation, provide only a 
temporary fix as the cancer develops resistance and recurs. 
 
In recent years, a paradigm shift has occurred. Rather than using drugs to kill the cancer, 
immunotherapy gets the immune system to kill cancer cells. Immunotherapy tends to 
work better when the immune cells recognize the cancer and infiltrate the tumor. In fact, 
for some types of cancer, the prognosis is better when the density of killer T cells (that 
can kill cancer cells) is higher in the tumor, even if no immunotherapy is employed. We 
will discuss this more below, but suffice it to say that while immunotherapy has shown 
promising results, we are still a long way from curing cancer.  
 
As Robert Austin has pointed out [4], such failure means that we just do not understand 
the basic principles behind cancer. We must think more broadly and physicists can help 
to expand the way we approach cancer. For example, an exclusive focus on signaling 
pathways and gene mutations ignores the physical characteristics of tumors. In 
particular, it ignores the spatial aspects of tumors, e.g., the spatial organization of cells 
and structures. Such spatial structure can affect the ways cells interact with each other 
and the structures in their environment. Studies on the spatial aspects of tumors could 
lead to different approaches and treatments. 
 
In this article, after an overview of cancer, immunology and immunotherapy, we give 
examples of how techniques used by physicists can be applied to quantify the spatial 
distribution of immune cells in tumors. These techniques include fractal dimensions and 
maximum entropy. 
 
Epidemiology 
Worldwide, the most commonly diagnosed cancers are lung, breast and colorectal 
cancer, and the most common causes of cancer death are lung, liver and colorectal 
cancer [1]. In the United States the most common cancers occur in the breast, lung and 
prostate, and the most common causes of cancer death are lung, colorectal and 
pancreatic cancer [5].  
 
What are the causes of cancer? Cancer risk factors include genes and family history. 
(A gene is a sequence of DNA bases that code for a corresponding sequence of amino 
acids that fold to form a protein molecule [6].) However, some cancers, such as breast 
and prostate cancer, are genetically heterogeneous. This means that different gene 
mutations are found in tumors from different patients with nominally the same type of 
cancer [7, 8].  For example, a study of 510 breast tumors from 507 patients found 30,626 
gene mutations, but mutations in only three genes occurred in more than 10% of the 
tumors [8].  
 
There are environmental factors such as carcinogens (cancer causing substances), 
radiation, and sunlight [5] that increase cancer risk. Lifestyle matters. Tobacco, alcohol, a 
diet lacking fruits and vegetables along with excess salt all increase the risk of cancer [5, 
9]. Obesity is a risk factor along with diabetes [5, 10-12]. In addition, certain occupations 
have an increased cancer risk, e.g., those with exposure to carcinogenic chemicals or 
asbestos [5]. People working the night shift may also have an increased risk of cancer 
[13-16]. 
 
Infectious agents, i.e., viruses and bacteria, were associated with 19% of cancers in 
2002 [17]. Examples include strains of the human papilloma virus (HPV) that can cause 
cervical cancer [18, 19], hepatitis B and C which increase the risk of liver cancer possibly 
through chronic inflammation [20, 21], HTLV-1 which can cause leukemia [22], 
Helicobacter pylori which is the primary cause of stomach ulcers and increases the risk 
of stomach cancer through chronic inflammation [23], and the Epstein-Barr virus which 
can cause Burkitt’s lymphoma and nasopharyngeal (nose and throat) cancer [24]. 
Chronic inflammation increases the risk of cancer because inflammation involves 
inflammatory cells and growth factors (substances that promote cell growth) that can 
encourage cancer cells to proliferate [25, 26]. 
 
Cancer mortality 
In spite of the large amount of time, money and effort that has gone into battling cancer, 
cancer death rates have not declined much in the United States. From 2004 to 2013, the 
overall cancer death rate in the US fell by 13% [2]. However, between 2012 and 2030, 
worldwide cancer death rates are projected to increase by 60% from 8 million to 13 
million per year [5]. 
 
What can be done to lower cancer mortality?  
Prevention is always the best choice. Having a healthy lifestyle lowers the risk. Avoid 
smoking, eat healthy, and exercise regularly. Cancer vaccines would be wonderful given 
how effective vaccines have been in preventing diseases caused by microorganisms. So 
far, though, the only cancer vaccine in widespread use is Gardasil which vaccinates 
against the strains of HPV that commonly cause cervical cancer [27] and some types of 
oropharyngeal (throat) cancer [28, 29].  
 
Early detection is key for successfully surviving cancer. Examples of cancer screening 
include the PSA (prostate serum antigen) blood test for prostate cancer, mammograms 
for breast cancer, and colonoscopies for colorectal cancer. Colonoscopies can actually 
help to prevent cancer of the colon and rectum by removing polyps that can later 
become cancerous. 
 
New technologies and approaches could lead to novel treatments. Recently there have 
been efforts in both the public and private sector to encourage physicists, 
mathematicians and engineers to collaborate with cancer researchers and clinical 
oncologists (medical doctors specializing in cancer). For example, the National Cancer 
Institute sponsors a Physical Sciences Oncology Network, and Stand Up to Cancer 
sponsors interdisciplinary convergence teams consisting of theoreticians and 
oncologists. Since cancer mortality is still high, the hope is that new perspectives and 
approaches from other fields could lead to new discoveries.  
 
Limitations on Current Cancer Research 
Scientific advances through research can lead to significant progress in the fight against 
cancer, but progress is slow. While new drugs have resulted from cancer research, there 
is the caveat that about 90% of preclinical cancer research results are not reproducible 
[30]. The biotech company Amgen tried to confirm the results of fifty-three landmark 
studies and found that they could only confirm the scientific findings in six cases (11%). 
In the cases where the results could not be reproduced, the investigators often 
presented the results of only one experiment rather than findings that were reflective of 
the entire data set. Amgen’s findings are consistent with other studies. For example, 
Bayer HealthCare in Germany reported that only about 25% of published preclinical 
studies could be validated [31]. 70% of the studies analyzed by Bayer involved cancer 
research, some of which might have also been analyzed in the Amgen study.  
 
More exchange of research information before publication could also help. For example, 
in physics, there is an online preprint archive (https://arxiv.org) where researchers post 
preprints before publication. Unfortunately, even though such an archive exists in biology 
(www.biorxiv.org), many biologists are not interested in utilizing such an archive [32]. 
One reason is that some biologists are afraid of other researchers stealing their results, 
which is rather ironic given the poor track record of reproducibility of biological research 
results [30, 31]. 
Introduction to Breast Cancer 
Since the rest of this article will focus on breast cancer, we begin with a brief 
introduction to the biology, structure and function of the breast [33, 34], or mammary 
gland, which is composed of both glandular and fatty tissue on top of the chest 
muscles. The function of the mammary gland is to produce milk. Milk is produced in 
small grapelike sacs called acini. A cluster of acini is called a lobule and a cluster of 
lobules is called a lobe. The milk produced in acini flows into a small channel called a 
ductule. Ductules merge to form milk ducts. Each lobe has one milk duct. If you look at 
the cross-section of a milk duct (see Figure 1), it is lined with mammary epithelial cells. 
(In general, epithelial cells line the inner surfaces of tubes and cavities in the body, 
e.g., the lungs and gastrointestinal tract. Carcinomas are cancers that originate from 
epithelial cells. The space inside the tube or cavity is called the lumen.) Surrounding 
the mammary epithelial cells is a layer of myoepithelial cells that help to squeeze the 
milk down the duct. Outside the myoepithelial cells is a tough outer sheath called the 
basement membrane. It is an example of extracellular matrix and is composed of 
proteins such as collagen. (Collagen is the most common protein in your body. It helps 
give elasticity to your skin.) 
 
 
 
Figure 1 (color online): Cross section of a normal milk duct showing the lumen, 
mammary epithelial cells, myoepitheial cells, and basement membrane. 
 
Most breast tumors start in the milk ducts or lobules. Typically the mammary epithelial 
cells start to proliferate and fill up the luminal space in the duct or acini. When this 
occurs to a substantial degree, this is known as ductal carcinoma in situ (DCIS). This is 
stage zero cancer. The phrase “in situ’’ literally means “in place”. In this case, it means 
that the cells have not broken through the basement membrane. If the epithelial cells 
continue to proliferate and break out of the duct and through the basement membrane, 
then this is called invasive ductal carcinoma. “Invasive’’ means that the cells have 
invaded tissue where they do not belong. Since invasive cancer cells break through a 
membrane, tumors are “wounds that do not heal” [35, 36]. 
 
Each year in the United States, over 200,000 women are diagnosed with invasive 
(stage 1 and higher) breast cancer; about 60,000 women are diagnosed with in situ 
(stage 0) breast cancer; about 40,000 women will die of breast cancer; and about 2000 
men are diagnosed with breast cancer [5].  
 
One of the more aggressive types of breast cancer is triple negative breast cancer 
(TNBC). Triple negative breast cancer cells lack appreciable expression of hormone 
epidermal growth factor receptor 2 (HER-2), estrogen receptors (ER) and progesterone 
receptors (PR). TNBC occurs in 15-20% of breast cancer cases. According to a recent 
study of TNBC, 76.2% of recurrences occurred within the first 5 years after surgery, 
with the median time of recurrence of 2.7 years [37]. We mention this type of breast 
cancer because some of the results below involve TNBC patients. 
 
Importance of the Tumor Microenvironment 
We tend to think of tumors as consisting solely of cancer cells, but in fact, tumors need 
a supporting environment known as the tumor microenvironment (TME) in order to 
survive and thrive [38]. The tumor microenvironment consists of blood vessels, various 
types of immune cells, fibroblasts, extracellular matrix, etc. Fibroblasts are cells that 
synthesize extracellular matrix and fibers such as collagen; fibroblasts are the most 
common cells in connective tissue.  
 
The evolution and progression of cancer depends on the tumor microenvironment. For 
example, the TME can play an important role in tumorigenesis, i.e., in the formation of 
tumors [39]. In particular, damage to the tumor microenvironment can cause pre-
malignant cells to become malignant [39-42]. For example, injecting a cancer-causing 
virus (Rous Sarcoma Virus or RSV) into the wing of a chicken produces a tumor at the 
injection site but not elsewhere, even though the virus has spread throughout the 
chicken. If the other wing is then wounded, a tumor is formed at the site of the wound 
[40]. In another experiment [41], pre-malignant cells (COMMA-D mammary epithelial 
cells with p53 mutations) placed on previously irradiated tissue (mammary fat pads in 
mice) were about four times more likely to form tumors than when the cells were 
placed on non-irradiated tissue. Furthermore, the tumors on the irradiated tissue were 
significantly larger and grew more quickly than those on the non-irradiated tissue. One 
reason that damaging the tumor microenvironment promotes tumorigenesis is that the 
growth factors (signaling proteins like TGF-β) that are produced as part of the wound-
healing process also promote the inception and growth of tumors [43] as well as 
metastasis [44].  
 
Lymph vessels are another component of the TME and can be thought of as a sewage 
system for cells. Cells are bathed in interstitial fluid from which they absorb nutrients 
and into which they dump waste. Lymph vessels take up interstitial fluid and conduct it 
to lymph nodes. The fluid inside lymph vessels is referred to as lymph. Eventually 
lymph is conveyed to blood vessels (veins). The lymphatic system is much more than 
just waste removal system; it is an important part of the immune system as we 
describe below. 
 
Brief Introduction to Lymphocytes 
Immunology is a fascinating and complex field of study. A good introductory text is [45]. 
Here we will only give a few brief facts to equip the reader with what will be needed to 
follow this article. White blood cells are immune cells. In this article we will focus on 
lymphocytes which are a subset of white blood cells. The two main categories of 
lymphocytes are T cells and B cells. B cells are best known for producing antibodies, 
which are proteins that recognize and attach to antigens, e.g., a specific protein on 
invading bacteria or viruses. The antibody tags the invader for destruction by other 
cells in the immune system, e.g., macrophages. However, B cells can perform other 
functions such as secreting signaling molecules called cytokines, and presenting 
antigens for T cells to inspect.  
 
T cells only recognize antigens in the form of pieces of proteins called epitopes that are 
displayed on the surface of cells in “display cases” that are called major 
histocompatibility complexes (MHCs). You can think of an MHC as a hot dog bun and 
the epitope as the hot dog [45]. The surfaces of T cells have T cell receptors (TCRs) 
which are antibody-like protein complexes that recognize and bind to specific antigens, 
i.e., specific epitopes in the MHCs. There are three main types of T cells: killer T cells 
(cytotoxic lymphocytes), helper T cells, and regulatory T cells. Cytotoxic T cells are 
able to kill unwanted cells, e.g., cancer cells and virus-infected cells. Helper T cells (Th 
cells) secrete cytokines which are chemical signaling molecules that direct the actions 
of other immune cells. Regulatory T cells suppress the immune system in order to keep 
it from overreacting or from acting inappropriately. In the lab, these different types of T 
cells can be distinguished by specific protein complexes on their surfaces. In particular, 
cytotoxic T cells and helper T cells express CD8 and CD4 co-receptors, respectively, 
on their surface. So we sometimes refer to killer T cells as CD8+ T cells, and helper T 
cells as CD4+ T cells. The plus sign in the superscript means that these cells stain 
positive for these protein markers by binding with their respective color-coded 
antibodies in the immunostaining process.   
 
The lymph nodes are small bean-shaped structures where immune cells, such as T 
cells, B cells and antigen presenting cells (APCs) that present antigens to certain 
lymphocytes such as T cells, meet and communicate. B cells and T cells that find their 
cognate antigens in lymph nodes can also be activated there. 
 
Brief Introduction to Immunotherapy 
Currently, there is a great deal of interest in using immunotherapy to treat cancer by 
activating the immune system to kill cancer cells. We describe below some ways in 
which this is being done. (For more details, see [45].) 
 
Monoclonal antibodies are antibodies produced in the laboratory that target specific 
proteins on the surface of cells. For example, some particularly aggressive types of 
breast cancer cells express high amounts of a growth factor receptor called Her2. 
When growth factor proteins bind to (or ligate) this surface receptor, the cancer cells 
proliferate. The monoclonal antibody Herceptin (trastuzumab) can bind to the Her2 
receptor and prevent the growth factor proteins from ligating the receptor, thus blocking 
the growth signals and slowing growth.  
 
Checkpoint Inhibitors: Antibodies that block the ability of cancer cells to turn off 
killer T cells 
Checkpoint inhibitors are monoclonal antibodies that are used to interrupt the way that 
cancer cells deactivate killer T cells. Here is how they work. Activated killer T cells 
express “checkpoint” protein receptors on their surface that prevent killer T cells from 
being overly active. For example, one of these checkpoint proteins is programmed 
death 1 (PD-1). When the ligand for PD-1, which is called PD-L1, binds to PD-1, the 
killer T cell does not function very well. Cancer cells with PD-L1 basically have a ‘key’ 
or ligand can effectively neutralize killer T cells by inserting the PD-L1 ‘key’ into the 
‘lock’ or receptor. Thus the cancer cells can prevent the killer T cells from killing the 
cancer cells. Checkpoint inhibitors are monoclonal antibodies that bind to, e.g., PD-1 or 
PD-L1, thus preventing the cancer cell from deactivating the killer T cell. It is analogous 
to taping over the keyhole or wrapping tape around the key so that the key cannot go 
into the keyhole. Checkpoint inhibitors prevent PD-L1 from binding to the PD-1. 
 
CAR T Cell Therapy: Engineering T cell receptors 
As we mentioned earlier, T cells have T cell receptors that bind to specific antigens. 
The TCRs on a given T cell are all the same and recognize one specific antigen which 
is referred to as the TCR’s cognate antigen. Different T cells have different TCRs. If the 
TCRs on a T cell recognize and bind to their cognate antigen, the T cell proliferates, 
i.e., makes identical daughter cells. CAR T cell therapy is a rapidly emerging cancer 
treatment in which the TCR is artificially engineered to recognize antigens on cancer 
cells. CAR stands for “chimeric” antigen receptor. (Chimera was a beast in Greek 
mythology that had the head of a lion, the body of a goat and a serpent’s tail.) The 
receptors on CAR T cells are designed to recognize and bind to specific surface 
proteins. It is important to note that these CAR T cognate antigens need not be 
presented by MHC molecules [45]. Cells that display these cognate proteins are then 
destroyed by the CAR T cells. CAR T cell therapy has been most successful in treating 
blood cancers such as leukemia and lymphoma. 
 
Spatial Distribution of Immune Cells 
Even for patients that do not receive immunotherapy, a high density of tumor infiltrating 
lymphocytes (TILs) is associated with a good prognosis in several types of cancers 
[46-48]. For example, higher densities of CD3+ and CD8+ T cells were associated with 
a lower rate of recurrence in colorectal carcinoma [49]. (CD3 is a marker for all T cells 
and CD8 is a marker for cytotoxic (killer) T cells.) In the case of patients with triple 
negative and HER2-positive breast cancers, a higher density of TILs is associated with 
a better prognosis [50]. (Triple negative breast cancer cells test negative for hormone 
epidermal growth factor receptor 2 (HER-2), estrogen receptors (ER) and progesterone 
receptors (PR).) While the prognostic value of the density of CD3+ and CD8+ T cells 
infiltrating tumors is well known, the clinical significance of other types of immune cells, 
such as B cells, is less clear [51, 52].  
 
Averaging cell densities over the entire tissue overlooks the spatial heterogeneity in the 
distribution of TILs within the tumor which may be clinically important [53-55]. If we 
view the tumor microenvironment in ecological terms, interactions between the different 
components of this ecosystem depend upon their spatial organization. Regional 
differences in selective pressures produce microhabitats resulting in phenotypic and 
genetic heterogeneity [56, 57]. So it is worth considering whether the spatial 
distribution of TILs is associated with a difference in clinical outcome, i.e., in whether or 
not the cancer recurs. 
 
Review of Previous Work on the Spatial Distribution of Immune Cells 
This leads to the more general problem of quantifying the spatial distribution (or 
arrangement) of cells in histology-based images with a single scalar number. There 
have been a number of efforts to quantify spatial heterogeneity of the tumor 
microenvironment based on comparing populations of cells [58]. For example, the 
Morisita-Horn index was used to quantify the spatial colocalization of tumor and 
immune cells, and it was found that significant colocalization was associated with a 
higher disease-specific survival in Her2-positive breast cancers [58, 59]. The Getis-Ord 
analysis [60] was used to locate immune hotspots where the clustering of immune cells 
was significantly above background. A combined immune-cancer hotspot score was 
found to be associated with good prognosis in ER-negative breast cancer [61]. A 
quantitative measure of the infiltration of immune cells into a tumor is the intratumor 
lymphocyte ratio (ITLR) which is defined as the ratio of the number of intratumor 
lymphocytes to the total number of cancer cells in a histological sample [62]. A high 
ITLR was found to be associated with good disease specific survival in ER-
negative/Her2-negative breast cancer [62]. 
 
Natrajan et al. [63] quantified the spatial heterogeneity in breast tumors with regard to 
the proportions of different cell types, e.g., cancer cells, lymphocytes and stromal cells, 
in different regions of the tumor by calculating the Shannon entropy and using 
Gaussian mixture models to fit the distribution of Shannon entropies. Their ecosystem 
diversity index (EDI) was the number of Gaussians needed to fit the distribution. They 
found that high EDI values were associated with high micro-environmental diversity 
and poor prognosis. Somewhat ironically, if most of the regions have high Shannon 
entropies such that a single Gaussian can be used to fit the distribution, then the EDI is 
low. 
 
Fractal dimensions [64] have been used to characterize the irregular morphology of 
tumors [65-67] and vasculature [68, 69] as well as subcellular structures such as 
mitochondria [70] and nuclei [71]. There are numerous ways to calculate fractal 
dimensions. In the box counting method, the number N of squares (each with area L2) 
needed to cover the 2D image of a tumor, say, is proportional to L-d, where d is the 
fractal dimension in the limit that L goes to zero (or a very small value). The more 
irregular the shape, the higher the fractal dimension is and the poorer the prognosis 
[65, 66]. 
 
Assuming that the structure of tumor tissue is reflected in the arrangement of cancer 
cell nuclei, Waliszewski et al. calculated several different fractal dimensions as well as 
the Shannon entropy and lacunarity to characterize the spatial distribution of cancer 
cell nuclei in prostate tumor tissue and compared the results to the corresponding 
Gleason scores in an attempt to find a more objective way to classify prostate tumor 
tissue [72, 73].  
 
 
Figure 2 (color online): Grid of squares overlaying a tissue image. 1’s (0’s) 
correspond to yes (no) answers to the question asked of each square, e.g., “Is 
there at least one B cell in the square?” 
 
Note that these approaches produce measures of the spatial distribution at a single 
length scale. More recently, to move beyond this limitation, we previously developed 
several unique statistical approaches that use coarse graining to examine the spatial 
distribution of various types of cells and structures within the tumor microenvironment 
over a range of length scales [74].  
Occupancy: The first technique is called ‘occupancy’. We begin with an image of tissue 
where different types of cells are labeled, i.e., immunostained, with different colors, 
e.g., killer T cells are bright red, B cells are cyan, etc. We overlay the tissue image with 
a grid of squares as in Figure 2. For each square, we then ask a binary (yes-no) 
question, e.g., “Is there at least one CD20+ B cell in the square?” If the answer is yes, 
we assign a ‘1’ to that square. If the answer is no, we assign a ‘0’ to the square. The 
occupancy g is the fraction of squares with 1’s, i.e., it is an estimate of the probability 
that a square will have a 1. To characterize the spatial distribution at different length 
scales, we varied the size of the squares in the grid and computed the occupancy as a 
function of L, the length of one side of a square. Note that the occupancy will be 
affected by the average cell density for questions such as “Is there at least one CD20+ 
B cell in the square?” because the higher the average cell density, the higher the 
probability that a square is assigned a ‘1’. We can plot the occupancy averaged over 
patients or samples versus the square size L (see Figure 3). We found that the area 
under the curve (AUC occupancy) differed between triple negative breast cancer 
patients with good and poor clinical outcome for CD20+ B cells and CD8+ T cells. We 
defined patients with no recurrence within 5 years after surgery as good clinical 
outcome (n=24) and patients who had recurrence within 3 years after surgery as poor 
clinical outcome (n=13). 
 
 
Figure 3 (color online): Occupancy for CD20+ B cells and CD8+ T cells vs. square 
size.  Notice the difference between good (blue) and poor (red) clinical outcome. 
The error bars indicate 95% confidence intervals. (A) CD20+ B cell occupancy 
before thinning (B) CD8+ T cell occupancy before thinning (C) CD20+ B cell 
occupancy after thinning the B cells to a density of 12 B cells/mm2 (D) CD8+ T 
cells occupancy after thinning the T cells to a density of 25 CD8+ T cells/mm2. 
 
Thinning: As we mentioned above, occupancy tends to increase with the average cell 
density. One way to remove the effect of density on the occupancy is to reduce, or thin, 
the density by randomly eliminating cells, e.g., CD8+ T cells, in the various images until 
the densities in all the tissue images have the same value as the image with the lowest 
density. Here is a simple example of how to randomly remove B cells. To randomly 
remove half the B cells from an image, you would go to each B cell, flip a coin, and 
remove the cell if you get ‘heads’ and keep the cell if you get ‘tails’. Figs. 3C and 3D 
show thinned plots of occupancy vs. square size L. The difference in the area under 
the curves (AUC) between good and poor clinical outcomes is statistically significant 
for B cells (p-value=8 x 10-4) but not for killer T cells (p-value = 0.3). This suggests that 
the spatial distribution, rather than the density, of B cells differs significantly between 
good and poor outcomes. 
 
p-value: In the previous paragraph we calculated the p-value under the null hypothesis 
to ascertain whether a quantity, such as the area under the curve, is clinically 
significant. The p-value is a standard statistical measure of a binary classifier [75]. 
Binary refers to our assumption that the clinical outcome is either good or poor. The p-
value is the probability of obtaining a random sample with a mean at least as far from 
that of the null hypothesis as is observed, assuming the null hypothesis is true. In our 
case, the null hypothesis states that the result could arise by random chance. The 
smaller the p-value is, the greater the probability that the null hypothesis is not valid. In 
general, results are considered significant if p<0.05. 
 
Fractal Dimension: Another way to characterize the number of boxes with 1’s and 
hence, the spatial distribution of cells, is with fractal dimension. Although a number of 
studies have used fractal dimension to analyze morphologies associated with tumors 
[65-71], we used it to quantify the spatial distribution of individual immune cells. While 
there are a number of different ways to define the fractal dimension, we chose to use a 
variation of the box counting method [76]. The number n(L) of squares with ‘1’ will be 
proportional to (1/Lδ) where δ is one type of fractal dimension. The constant of 
proportionality depends on the size of the tissue that dictates the number of boxes 
covering the tissue. To avoid this, we found it convenient to define the fractal 
dimension s to be given by: s(L) = -d[log n(L)]/d[log L]. (Note that unlike the more 
common definition of the box-counting fractal dimension, we do not take the limit Là0, 
because we are interested in the distribution of individual cells at different length 
scales.) We used a different variable, s(L), rather than δ, since n(L) typically does not 
follow a simple power law as L is varied. 
 
Both occupancy and fractal dimension depend on the number of squares with 1’s, so 
there must be a simple relation between the dependence of occupancy on L and fractal 
dimension d. To find the relation, consider the following. Suppose the total number 
N(L) of squares covering the image of the tissue goes as (1/LD). Then if n(L) ~ (1/Lδ), 
the occupancy g = n(L)/N(L) ~ LD-δ. Note that D need not be equal to 2 since the image 
of the tissue may be irregular or there may be regions that were not imaged. 
 
 
  
Figure 4 (color online): (A) Diagram illustrating how fractal dimension (FD) 
difference can distinguish the difference between spread out cells and clustered 
cells. The upper halves (above the red lines) of the two images show points that 
are spread out while the lower halves show clustered points. At long length 
scales (big boxes) the FD is 2 in the upper half but not in the lower half. At small 
length scales (small boxes), there is the same number of boxes with points and 
hence the same fractal dimension. The fractal dimension difference is greater in 
the upper half because the points are more spread out in the upper half. (B) The 
Gaussian method for density estimation. Diagram illustrates hotspot analysis. 
Three large blue points indicate the locations of three cells. Each cell’s 
contribution to the local density is represented by a Gaussian distribution. The 
mountain over the three cells represents the sum of their Gaussian weights, i.e., 
the local cell density. The small red points are the grid points where the 
Gaussian weights are summed.  
 
Fractal Dimension Difference: To see if cells are clustered or spread out, we looked at 
the difference Δs in fractal dimension between large and small length scales: Δs = 
sLarge – ssmall, where sLarge is the fractal dimension at large length scales and ssmall is the 
fractal dimension at small length scales. The small and large length scales should 
roughly bracket the typical, or median, nearest neighbor distance between cells of the 
same type, e.g., CD8+ T cells. In all the cases we examined, Δs > 0. If Δs is large, it 
means that the cells are more dispersed, i.e., more spatially spread out because they 
appear more two-dimensional at large length scales and more zero-dimensional (point-
like) at small length scales (See Figure 4A).  If Δs = 0, the fractal dimension does not 
change with length scale and the system is self-similar. If Δs is small, then the system 
is closer to being fractal and the cells are more clustered. 
 
Hotspot Analysis: Another way to see if the cells are clustered or spread out is to 
determine the fraction of area where there are density ‘hotspots’, i.e., where the density 
of cells of a given type, e.g., CD20+ B cells, is above average. To do this analysis, each 
CD20+ B cell, say, is represented by a two-dimensional Gaussian distribution that 
represents the local density due to that cell. The width of the Gaussian is 2σ where σ2 
is the variance of the Gaussian. We then impose a square lattice of points (with lattice 
constant a) over the image and add the Gaussian weights at each lattice point (see 
Figure 4B). The resulting sum is the local CD20+ B cell density. We then average the 
densities over the entire lattice of points and calculate the fraction of lattice points 
greater than the average for that image. We refer to this as the fraction of the (image) 
area with hotspots. Note that this fraction is independent of the value of the average B 
cell density since the hotspots are measured relative to the average density in each 
particular image. We then average over images and vary σ. The larger the fraction of 
hotspots is, the more spread out the cells are. 
 
Our hotspot analysis differs from the Getis-Ord hotspot analysis [58, 60] which requires 
dividing the image up into regions and depends on the cell counts in neighboring 
regions. Our hotspot method is completely local in the sense that the cell density at 
one grid point does not depend on the density at neighboring points. 
 
In applying these techniques to the B cells and killer T cells in the tumors of 37 triple 
negative breast cancer patients, we found that the fractal dimension difference and the 
area under the curve of hotspot fraction vs. σ is larger for good outcome (see Figure 5), 
indicating that these cells are more spread out in the cases where the tumor does not 
recur and more aggregated in cases where there is recurrence.  
 
 
Figure 5 (color online): (A-B) Fraction of area with (A) B cell hotspots (B) CD8+ T 
cell hotspots vs. σ for good outcome (blue) and poor outcome (red). The error 
bars correspond to 95% confidence intervals. (C) Log-log plot of the number of 
squares with at least one CD20+ B cell vs. the inverse box size. (Logarithms are 
base e.) At long length scales (200-600 microns on the left side of plot), the mean 
fractal dimension s (slope) is 1.4 for good outcome (blue) and 1.12 for poor 
outcome (red). The p-value for good vs. poor outcome is 0.02 at long length 
scales. At short length scales (10-40 microns on the right side of the plot), the 
mean fractal dimension is 0.61 for good outcome and 0.74 for poor outcome. The 
p-value for good vs. poor outcome is 0.1 at short length scales. The fractal 
dimension difference Δs = 0.78 for good outcome is greater than Δs = 0.38 for 
poor outcome. So B cells are more spread out for good outcome. The p-value 
associated with Δs is 9 x 10-5. (D) Log-log plot of the number of squares with at 
least one CD8+ T cell vs. the inverse box size. At long length scales (200-600 
microns on the left side of plot), the mean fractal dimension s (slope) is 1.74 for 
good outcome (blue) and 1.46 for poor outcome (red). The p-value for good vs. 
poor outcome is 0.0005 at long length scales. At short length scales (10-40 
microns on the right side of the plot), the mean fractal dimension is 0.46 for good 
outcome, 0.38 for poor outcome. The p-value for good vs. poor outcome is 0.2 at 
short length scales. The fractal dimension difference Δs = 1.28 for good outcome 
is greater than Δs = 1.08 for poor outcome. So CD8+ T cells are more spread out 
for good outcome. The p-value associated with Δs is 0.006. (C-D) Black dashed 
lines show the least squares linear regression fit at long and short length scales. 
Because different images had different overall areas, we normalized the number 
n(L) of boxes with 1’s by the total number N(L) of boxes with cells in computing 
the fractal dimension; thus the y-axis values are negative.  
 
Nearest neighbor (NN) distances between cells of a given type: An a priori obvious way 
to quantify how spread out the cells of a given type, e.g. B cells, are in an image would 
be to measure the mean or median NN distances between those cells. However, most 
B cells are quite close (5-20 µm) to another B cell, so the NN distance just reflects the 
(inverse of the) local cell density rather than the spatial dispersion at long length 
scales. However, if the B cells (or cells of a given type) are thinned, then the mean or 
median nearest neighbor distances can be a good measure of the spatial dispersion of 
cells [74].  
 
A Maximum Entropy Approach to Quantifying the Spatial Distribution of Immune 
Cells 
 
Entropy is a measure of disorder. The greater the number of configurations or the 
number of ways of arranging things, the greater the entropy is. Mathematically, the 
entropy is the logarithm of the number of states or ways of arranging things. Since 
there can be millions of immune cells in an image of the tissue, the number of ways of 
arranging all these cells and hence, the associated entropy is huge. To reduce the 
entropy to a manageable value, we took the following approach. We divided the image 
of the tissue into blocks of size L x L. Each block or matrix was subdivided further into 
3 x 3 squares like tic-tac-toe. As before, for each square, we then ask a binary (yes-no) 
question, e.g., “Is there at least one T cell in the square?” If the answer is yes, we 
assign a 1 to that square. If the answer is no, we assign a 0 to the square. There are a 
total of 29 or 512 possible states. So the entropy for total randomness (all states 
equally likely) is S0 = ln(512). We chose 3 x 3 matrices in order to obtain meaningful 
statistics, i.e., we want the total number of possible states to be much less than the 
number of samples (statistical trials). Let P(xi) be the probability of finding the ith 
configuration where i varies from 1 to 512. Then the entropy is  
 	S = − P xi( )i=1512∑ ln P xi( )⎡⎣ ⎤⎦   (1) 
Maximum Entropy: Maximum entropy is a widely used technique to find the probability 
P(xi) subject to the constraint that it produces the observed expectation values of 
various quantities of the distribution [77, 78]. It is a minimalist approach in that it does 
not impose any other constraints or assumptions. It works in the following way. Let 
fµ(xi) be the µth measureable quantity when the system is in the state xi. The observed 
expectation value is <fµ>expt. The constraint is that the probability P(xi) satisfy 
 
P xi( )fµ xi( ) = fµ expti∑ . To do this we maximize the entropy functional: 
  
 	 !S P x( )⎡⎣ ⎤⎦ = − P(xi )lnP(xi )i∑ − λµ P(xi ) fµ (xi )− fµ expti∑⎡⎣⎢ ⎤⎦⎥µ=0K∑   (2) 
where λµ are the Lagrange multipliers that are adjusted so that the constraints are 
satisfied. Maximizing  !S  yields the probability 	P(xi )= 1Z exp − λµ fµ (xi )µ=1K∑⎡⎣⎢ ⎤⎦⎥  where Z is the 
normalization constant. The entropy is then given by 
	
S = − P xi( )
i
∑ ln P xi( )⎡⎣ ⎤⎦ . 
Moments of the Distribution, Probabilities and Entropies [79]: The observables that set 
the constraints are the moments of the distribution. The zeroth moment is the 
normalization condition on the probability. In our case, the first moment is the average 
matrix occupancy <p>, i.e., the average fraction of squares that have a ‘1’ in a matrix of 
3 x 3 squares. If P1(xi) is normalized and is subject to the constraint that it gives the 
right value of <p>, then this gives the first order entropy S1. The connected information 
of order 1 is defined by I1 = S0 – S1 and tells us how much the occupancy or density 
reduces the entropy from the completely random case [79]. (Note that this definition of 
occupancy is slightly different from our earlier description where we placed a grid of 
squares covering the image of the tissue, and defined the occupancy to be the fraction 
of squares with 1’s.) 
 
 
Figure 6: The five two-square and ten three-square patterns possible for a 3 x 
3 matrix, ignoring translations, rotations, and reflections. The two-square 
(three-cell) pattern has two (three) 1’s and the blank squares can be either 1 
or 0. Each pattern corresponds to a state. Rotations, translations and 
reflections of a given pattern are counted as part of the same state. The 
fraction of times that a given state µ occurs equals <fµ>expt in Eq. (2). 
 
The second moment consists of the average occurrence rates of various patterns with 
two squares that have 1’s. Ignoring translations, rotations and reflections, there are 5 
types of such patterns in a matrix of 3 x 3 squares as shown in Figure 6. If P2(xi) is 
normalized and gives the right value of <p> as well as those of the 2-square 
occurrence rates, then this gives the second order entropy S2. The connected 
information of order 2, I2 = S1 – S2, tells us how much the constraints of the second 
moment reduces the first order entropy. Similarly, the third moment corresponds to 10 
different arrangements of 3 squares that have ‘1’ in a 9-square matrix, ignoring 
translations, rotations and reflections as shown in Figure 6. P3(xi) gives the third order 
entropy S3, and the connected information of order 3 is given by I3 = S2 – S3. The multi-
information is defined by IN = S0 – SN  where SN is given by using the actual histogram 
distribution found from the data.  
 
Relation of Occupancy and I1: We note that I1 is related to occupancy in the following 
way for a 3 x 3 matrix of squares. Let the occupancy p be the probability that a square 
will have a '1'. Let q = (1-p) be the probability that a square will have a '0'. Let xi denote 
a given state or arrangement of 1's and 0's in a 3x3 matrix. Then the probability 
 
!Pn,p xi( )  of a given state with n 1's is given by  !Pn,p xi( ) = p
nq9−n . The first order entropy 
just depends on the occupancy and is given by  
 
 
S1 = − !Pn,p xi( )ln
i=1
512
∑ !Pn,p xi( )⎡⎣ ⎤⎦ = −
9!
n! 9 − n( )!
⎡
⎣
⎢
⎢
⎤
⎦
⎥
⎥
!Pn,p
n=0
9
∑ ln !Pn,p⎡⎣ ⎤⎦   (3) 
where we used the binomial coefficient to reduce the number of terms in the sum from 
512 to 10 since the binomial coefficient gives the number of ways to arrange n 1’s in a 
3 x 3 matrix. The connected information I1 = S0 – S1 where S0 = ln(512) = 6.238. Note 
that I1 = 0 at p = q = 0.5 because  
!Pn,p=0.5 = 1/ 512 . We can explicitly evaluate Eq. (3) 
and compute I1 versus occupancy. This is plotted in Figure 7. Notice that for 
occupancy p > 0.5, the greater the occupancy, the higher I1 is, whereas for p < 0.5, the 
greater the occupancy, the lower I1 is. 
 
 
Figure 7: I1 vs. occupancy. I1 = 0 and has a minimum when the occupancy = 0.5 
because that is where there is a 50% chance of having a 0 or a 1 in each square. 
So the entropy S0 = S1. 
Kullback-Leibler Divergence: Another way to compare the different probability 
distributions, e.g., P1 and P2, is through the Kullback-Leibler (KL) divergence [80, 81] 
(or relative entropy): 
 
 
D12 = − P1 xi( )ln
P2 xi( )
P1 xi( )
⎛
⎝
⎜
⎞
⎠
⎟
i
∑   
This is a measure of how different a probability distribution P2 is from a reference (a 
priori) probability distribution P1. If the distributions are identical, then D12 = 0; 
otherwise D12 is always positive. 
 
Application of Maximum Entropy to Breast Cancer 
Triple Negative Breast Cancer Patient Cohort 
We have used our maximum entropy approach to analyze the spatial distribution of 
various types of TILs in 2D images of tumor-infiltrating lymphocytes (TILs) in 
immunohistochemistry-based images of primary tumor tissue from 37 patients with 
triple negative breast cancer (TNBC) prior to any treatment. In this study, we defined 
patients with no recurrence within 5 years after surgery as good clinical outcome 
(n=24) and patients who had recurrence within 3 years after surgery as poor clinical 
outcome (n=13). All the patients were subsequently treated with standard 
chemotherapy; some also had radiotherapy.  
 
 
Preparation of Images: Multispectral Staining of Different Cell Types 
 
To analyze the spatial distribution of various types of TILs, we first identified the 
locations of cells in 2D images of archived formalin fixed paraffin embedded (FFPE) 
tumor tissues from 37 TNBC patients. Each cell type was immunostained and labeled 
with a different color chromophore. This means that the tissue is treated with an 
antibody that binds to a protein that is specific to a certain cell type. For example, the 
protein CD3 is expressed on all types of T cells but not on B cells. So if we attach a 
green colored molecule or chromophore to CD3 antibodies, then T cells that bind the 
antibodies will appear green.  Each image was restricted to tumor-associated regions 
and excluded necrotic and fibrotic areas determined by a pathologist. (Necrotic tissue 
consists of dead cells. Fibrotic tissue has excess fibrous connective tissue, e.g., scar 
tissue.) 
RESULTS 
Entropies vs. Length Scale 
In Figure 8, we plot S1, S2, S3 and SN versus matrix size for good and poor outcome for 
B cells and CD8+ T cells. (Recall that a matrix has 3x3 squares.) Notice that there is a 
distinct difference between good and poor outcome, though the shape of the curves is 
similar because the densities of B cells is comparable between good (3.0 × 102/mm2) 
and poor (2.3 × 102/mm2) outcome. If we integrate under the curves to get the area 
under the curve (AUC), then good outcome has a larger AUC for B cells compared to 
poor outcome. For example, the B-cell AUC for SN is 31 for good outcome compared to 
22 for poor outcome. This difference is significant (p-value=0.01) and reflects the fact 
that the B cells are more spread out for good outcome and more aggregated for poor 
outcome. However, there is no significant difference between the good and poor 
outcome AUC for CD8+ T cells because the curves cross. The difference between 
good and poor outcome in the shape of the curves for CD8+ T cells is due the 
significant difference in densities between good (4.5 x 104/mm2) and poor (2.1 x 
104/mm2) outcome. The maximum in S1 vs. matrix size occurs at the matrix size where 
the probability p of having at least one CD8+ T cell in a square is closest to 0.5. Recall 
that the case of p = q = 0.5 gives the maximum entropy S0. Since good outcome has a 
higher CD8+ T cell density, the entropy curves reach a maximum at a smaller matrix 
size compared to poor outcome. 
 
 
 
Figure 8 (color online): Entropies S1, S2, S3 and SN vs. matrix size for (A-D) CD20+ 
B cells and (E-H) CD8+T cells. Blue solid lines are for good outcome and red 
dashed lines are for poor outcome. The error bars represent 95% confidence 
intervals. (A) S1 (B) S2 (C) S3 (D) SN (E) S1 (F) S2 (G) S3 (H) SN 
 
Notice that for a given cell type and outcome, the entropy curves in Fig. 8 are similar to 
those for S1. This is because S1 dominates the entropy. This is clearly seen in Figs. 9 
and 10 where the connected information moments (I1, I2, I3, and IN) and KL divergences 
(D01, D12, D23, and D0N) are plotted for B cells and CD8 T cells. One can see that 
similar information is conveyed for the pairs (I1 and D01), (I2 and D12), etc. Both 
connected information moments and KL divergences are ways to compare two 
distributions. I1 and D01 differ between good and poor outcome but there is no 
noticeable dependence on outcome for I2, I3, D12, and D23. In fact, I3 and D23 are 
negligible. I2 and D12 are nonzero and reflect clustering of the cells since the cells need 
to be in the same matrix. IN is similar to I1 because it is dominated by I1, and D0N is 
similar to and dominated by D01. The fact that the difference between good and poor 
outcomes is only noticeable for the first moment (I1 and D01) is why we focused on 
quantities described earlier like occupancy, fractal dimensions, and fraction of area 
with density hotspots. 
 
 
 
Figure 9 (color online): Information moments and Kullback-Leibler divergences 
vs. matrix size for CD20+ B cells. Blue solid lines are for good outcome and red 
dashed lines are for poor outcome. The error bars represent 95% confidence 
intervals. (A) D01 (B) I1 (C) D12 (D) I2 (E) D23 (F) I3 (G) D0N (H) IN. 
 
 
Figure 10 (color online): Information moments and Kullback-Leibler divergences 
vs. matrix size for CD8+ T cells. Blue solid lines are for good outcome and red 
dashed lines are for poor outcome. The error bars represent 95% confidence 
intervals. (A) D01 (B) I1 (C) D12 (D) I2 (E) D23 (F) I3 (G) D0N (H) IN. 
 
 
DISCUSSION 
 
We have seen that going beyond the density of immune cells, e.g., B cells or T cells, 
and looking at their spatial distribution can reveal differences associated with clinical 
outcome, i.e., whether or not cancer recurs. Unlike previous approaches to quantify the 
spatial distribution of cancer and immune cells, we have developed techniques that 
span a range of length scales. Occupancy, fractal dimension difference and the fraction 
of area with density hotspots are useful for determining to what degree cells are spread 
out or aggregated. In our maximum entropy approach, S1, I1 and D01 are sensitive to 
the density of cells while higher moments, e.g., S2, I2 and D12, are a way to ascertain 
the spatial correlation of cells on different length scales.  
 
Our findings raise a number of important questions about the spatial distribution of 
TILs. First, what determines the spatial distribution of TILs? Certainly, chemical signals, 
i.e., cytokines and chemokines help to dictate where immune cells go. In addition, we 
speculate that the somewhat fractal spatial distribution of TILs may arise from the 
branching trajectories of the B and T cells as they patrol the tissue. Branching 
structures such as trees and plant roots are self-similar, and hence fractal, because 
they look the same over a range of length scales, i.e., over a range of magnifications. It 
may be that the paths that B and T cells travel along have a branching structure 
because these cells have to go around physical obstacles such as other cells, blood 
vessels, and collagen fibers. In addition, T cells are known to follow along the outside 
of blood vessels and collagen fibers [82, 83] which can have a branching architecture. 
 
Second, why do the spatial distributions of B and T cells differ between good and poor 
clinical outcome? In particular, one could also ask why B and T cells are more spread 
out for good clinical outcome as found in Ref. [74]. One possibility is that the difference 
in spatial distribution reflects differences in the spatial topography (obstacles) of the 
tumor microenvironment. In FFPE tissue sections, we performed immunohistochemical 
staining of collagen I which did not yield differences in the spatial distribution of 
collagen I between good and poor outcome (data not shown). This indicates that 
differences in physical topography may not be the explanation.  
 
It may be that when they are more spread out, these types of cells are better at 
immune surveillance in good outcome patients. For example, antigen-presenting B 
cells may be more likely to acquire and successfully present cancer neo-antigens to 
helper T cells if they are able to interact both with cancer cells and other immune cells 
by spreading out. In addition, cytokine secreting B cells may cover a larger area with 
signaling molecules. In either case, an even spatial distribution is a more effective 
strategy for B and T cell surveillance than sequestration in small parts of the tumor. It 
may also be that B and T cells in good outcome patients are more responsive to 
chemokines secreted by tumor cells and are more successful in finding their cognate 
(matching) antigens within the tumor microenvironment as in a recently published study 
[84].  
 
Third, it is rather odd prima facie that we are able to give a prognosis with any degree 
of accuracy based on tumor tissue that has been removed from a patient. The cells in 
the surgically removed tissue are no longer in the patient, yet their spatial distribution 
can be used to predict whether or not the cancer will recur with an accuracy of 60-80%. 
The reason for this is not understood. It may be that spatially dispersed B and T cells 
are associated with more immune engagement and the production of more memory B 
and T cells, leading to a better long-term outcome. 
 
The statistical techniques that we have developed to quantify spatial distributions are 
novel. Unlike previous efforts to analyze spatial distributions at a single length scale, 
we have examined how the spatial distribution varies with length scale and how that 
can shed light on whether the cells are clustered or spread out spatially. On a more 
general level, these approaches are flexible and can be applied to a broad spectrum of 
problems. There are straightforward extensions of these approaches, e.g., to quantify 
the spatial distributions of various kinds of cells in metastatic tumors or to ascertain 
which patients are good candidates for various therapeutic treatments. However, one 
can go beyond simply the spatial distribution of cells or discrete entities. In determining 
the occupancy, fractal dimension and the difference in fractal dimensions, we laid down 
a grid of squares and asked a binary yes-no question of each square. In this paper, we 
asked questions like “Is there at least one CD20+ B cell in this square?” However, in 
other contexts, one may be interested in other questions such as that of co-localization. 
For example, one could ask “Does the square have at least one T cell that is within 50 
microns of a dendritic cell?” or “Does the square have at least one B cell and one T cell 
within 25 microns of a blood vessel?” Furthermore, these approaches could be applied 
to image analysis outside of biology, e.g., the distribution of galaxies in astrophysics. 
 
In conclusion, we have presented novel techniques to quantify the spatial distribution of 
point-like objects. In applying these techniques to B and killer T cells in tumors, we 
found that the spatial arrangement of these immune cells is strongly correlated with 
clinical outcome, i.e., breast cancer recurrence. This highlights the importance of these 
immune cells in cancer and raises new questions about their role in preventing cancer.	
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